Alfresa Holdings Corp (2784):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Alfresa Holdings Corp (2784) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3425
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:23
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Alfresa Holdings Corp (Alfresa) is a manufacturer and marketer of pharmaceuticals, diagnostic reagent and medical devices. The company offers ethical pharmaceuticals wholesaling, self-medication products and manufacturing. It’s ethical pharmaceutical wholesaling business supplies diagnostic reagents, medical devices and equipment to hospitals, clinics, dispensing pharmacies and other institutions. Alfresa’s self-medication products wholesaling business offer health foods, supplements, cosmetics, and other products to drugstores and pharmacies. The company offers comprehensive healthcare services by broadening its operational scale and scope. It markets its products in Japan and abroad. Alfresa is headquartered in Chiyoda-Ku, Tokyo, Japan.

Alfresa Holdings Corp (2784) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Alfresa Holdings Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Alfresa Holdings Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Alfresa Holdings Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Alfresa Holdings Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Alfresa Holdings Corp, Medical Devices Deals, 2012 to YTD 2018 10
Alfresa Holdings Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Alfresa Holdings Corp, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Alfresa Pharma to Acquire 41 Products from Daiichi Sankyo 12
Partnerships 13
Sanofi Enters Into Co-Development Agreement With Alfresa For Antiepileptic Drug 13
Acquisition 14
Alfresa to Acquire Sannova from Eisai 14
Alfresa Completes Acquisition Of Tokiwa Yakuhin 15
Alfresa Acquires Remaining 48.98% Stake In Kowa Pharma 17
Alfresa Holdings Corp – Key Competitors 18
Alfresa Holdings Corp – Key Employees 19
Alfresa Holdings Corp – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 22
Corporate Communications 22
Dec 21, 2017: Alfresa Announces Appointment and Resignation for Representative Directors 22
Appendix 23
Methodology 23
About GlobalData 23
Contact Us 23
Disclaimer 23

List of Tables
Alfresa Holdings Corp, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Alfresa Holdings Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Alfresa Holdings Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Alfresa Holdings Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Alfresa Holdings Corp, Deals By Therapy Area, 2012 to YTD 2018 8
Alfresa Holdings Corp, Medical Devices Deals, 2012 to YTD 2018 10
Alfresa Holdings Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Alfresa Pharma to Acquire 41 Products from Daiichi Sankyo 12
Sanofi Enters Into Co-Development Agreement With Alfresa For Antiepileptic Drug 13
Alfresa to Acquire Sannova from Eisai 14
Alfresa Completes Acquisition Of Tokiwa Yakuhin 15
Alfresa Acquires Remaining 48.98% Stake In Kowa Pharma 17
Alfresa Holdings Corp, Key Competitors 18
Alfresa Holdings Corp, Key Employees 19
Alfresa Holdings Corp, Subsidiaries 20

List of Figures
Alfresa Holdings Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Alfresa Holdings Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Alfresa Holdings Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Alfresa Holdings Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Alfresa Holdings Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Alfresa Holdings Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Alfresa Holdings Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Alfresa Holdings Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Alfresa Holdings Corp, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Alfresa Holdings Corp (2784):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bioton SA (BIO):企業の財務・戦略的SWOT分析
    Bioton SA (BIO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Vectura Group plc:企業の戦略・SWOT・財務分析
    Vectura Group plc - Strategy, SWOT and Corporate Finance Report Summary Vectura Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Banesco Banco Universal CA:企業の戦略・SWOT・財務分析
    Banesco Banco Universal CA - Strategy, SWOT and Corporate Finance Report Summary Banesco Banco Universal CA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Aduro BioTech Inc (ADRO):企業の財務・戦略的SWOT分析
    Aduro BioTech Inc (ADRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Biomunex Pharmaceuticals:製薬・医療:M&Aディール及び事業提携情報
    Summary Biomunex Pharmaceuticals (Biomunex) is a biopharmaceutical company that discovers and develops bispecific antibody therapeutics for the treatment of cancer. The company’s portfolio of pipeline products incldes BMX-101, which is developed as a novel immunotherapeutic treatment for relapsed an …
  • Auris Medical Holding Ltd (EARS):企業の財務・戦略的SWOT分析
    Auris Medical Holding Ltd (EARS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • maxingvest ag:企業の戦略・SWOT・財務分析
    maxingvest ag - Strategy, SWOT and Corporate Finance Report Summary maxingvest ag - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Tempo Beverages Ltd.:企業の戦略・SWOT・財務情報
    Tempo Beverages Ltd. - Strategy, SWOT and Corporate Finance Report Summary Tempo Beverages Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Bashas’ Inc.:企業の戦略・SWOT・財務情報
    Bashas' Inc. - Strategy, SWOT and Corporate Finance Report Summary Bashas' Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Evolution Mining Ltd:企業のM&A・事業提携・投資動向
    Evolution Mining Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Evolution Mining Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Olvi plc:企業の戦略・SWOT・財務情報
    Olvi plc - Strategy, SWOT and Corporate Finance Report Summary Olvi plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Huawei Investment & Holding Co., Ltd.:企業の戦略・SWOT・財務情報
    Huawei Investment & Holding Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Huawei Investment & Holding Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Petro-Hunt LLC:石油・ガス:M&Aディール及び事業提携情報
    Summary Petro-Hunt LLC (Petro-Hunt) is an oil and gas exploration and production company. The company offers services in the areas of pipeline exploration and production; gas processing, oil and gas technology; refining, real estate and ranching. Its exploration and production activities include dri …
  • Agilent Technologies Inc (A)-医療機器分野:企業M&A・提携分析
    Summary Agilent Technologies Inc (Agilent) is a provider of instruments, reagents, software, services and consumables for comprehensive laboratory workflow. Its product portfolio comprises atomic absorption systems, bioanalyzers, gene expression microarrays and automation systems, among others. The …
  • BioView Ltd (BIOV):医療機器:M&Aディール及び事業提携情報
    Summary BioView Ltd (BioView) develops, manufactures and markets automated cell imaging and analysis solutions, which incorporate proprietary imaging, analysis and review technology. The technology provides automatic control of fully motorized fluorescent and bright-field microscopes fitted with hig …
  • Dohler GmbH:戦略・SWOT・企業財務分析
    Dohler GmbH - Strategy, SWOT and Corporate Finance Report Summary Dohler GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Academic Medical Center-製薬・医療分野:企業M&A・提携分析
    Summary Academic Medical Center (AMC), a subsidiary of University of Amsterdam is a medical center that offers research and educational services. The center offers services such as treatment of patients, medical research and medical education. It provides medical treatments and services for various …
  • The Bank of Kyoto Ltd:企業の戦略・SWOT・財務情報
    The Bank of Kyoto Ltd - Strategy, SWOT and Corporate Finance Report Summary The Bank of Kyoto Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Holloway Lodging Corporation:戦略・SWOT・企業財務分析
    Holloway Lodging Corporation - Strategy, SWOT and Corporate Finance Report Summary Holloway Lodging Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Hydra Biosciences Inc-製薬・医療分野:企業M&A・提携分析
    Summary Hydra Biosciences Inc (Hydra) is a biopharmaceutical company that develops novel drugs. The company’s pipeline candidate HX-100 is developed to treat diabetic neuropathy and allergic asthma. It offers other drugs for the therapeutic areas including inflammation, pain, renal, anxiety and pulm …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆